β
Outcome MeasurePersonality / Psychological

CADSS

Clinician-Administered Dissociative States Scale

4 Papers in Blossom

Outcome Data Across Studies

Reported results for CADSS across 4 studies with quantitative data.

Outcome data across 13 study arm–timepoint observations
SD
Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial
2018Safety
Ayahuasca(experimental)014———
Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial
2018Safety
Placebo(inactive)015———
Intravenous Ketamine for Late-Life Treatment-Resistant Depression: A Pilot Study of Tolerability, Safety, Clinical Benefits, and Effect on Cognition
2022Safety
Ketamine IV(experimental)025———
Intravenous Ketamine for Late-Life Treatment-Resistant Depression: A Pilot Study of Tolerability, Safety, Clinical Benefits, and Effect on Cognition
2022Safety
Ketamine IV(experimental)025———
Intravenous Ketamine for Late-Life Treatment-Resistant Depression: A Pilot Study of Tolerability, Safety, Clinical Benefits, and Effect on Cognition
2022Safety
Ketamine IV(experimental)025———
A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression
2023Safety
Dose A(experimental)0————
A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression
2023Safety
Dose A(experimental)7————
A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression
2023Safety
Dose B(experimental)0————
A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression
2023Safety
Dose B(experimental)7————
A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression
2023Safety
Individualised(experimental)0————

Papers Using CADSS

Open Accessindividual

GH001 vs Placebo in Patients With Treatment-Resistant Depression A Randomized Clinical Trial

This randomised, double-blind, placebo-controlled phase 2b trial (n=81) found that a single-day inhaled synthetic mebufotenin treatment (GH001; 5-MeO-DMT) reduced depression symptoms more than placebo in adults with treatment-resistant depression, with remission in over half of those treated. No severe or serious adverse events were reported during the placebo-controlled period.

Published
Journal
JAMA Psychiatry
Authors
Cubała, W. J., Bajbouj, M., Bauer, M., Baune, B. T., Cardoner, N., Devlin, F., Doolin, K., Dueñas Herrero, R. M., Elices, M., Feeney, A., Gałuszko-Węgielnik, M., Jakuszkowiak-Wojten, K., Janů, L., Kelly, J. R., Ledden, K., Maclsaac, R., Madero, S., McInerney, S. J., Montejo, A. L., Nawka, A., Páleníček, T., Pérez Solà, V., Ramaekers, J. G., Reif, A., Ritter, P., Ryan, F., Svendsen, C. B., Sweeney, C., Terwey, T. H., Trivedi, M. H., Valcheva, V., Vieta, E., Thase, M. E.
Open Accessindividual

A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression

In a Phase 1/2 trial of 16 adults with treatment‑resistant depression, inhaled 5‑MeO‑DMT (GH001) was evaluated as single doses (12 mg, 18 mg) and as an individualized regimen of up to three ascending doses in one day. GH001 was well tolerated and produced ultra‑rapid antidepressant effects, with remission at day 7 in 7/8 (87.5%) patients in the individualized dosing group, markedly higher than the single‑dose arms.

Published
Journal
Frontiers in Psychiatry
Authors
Reckweg, J., van Leeuwen, C., Theunissen, E. L., Mason, N. L., Paci, R., Terwey, T. H., Ramaekers, J. G.
Paywallindividual

Intravenous Ketamine for Late-Life Treatment-Resistant Depression: A Pilot Study of Tolerability, Safety, Clinical Benefits, and Effect on Cognition

This open-label study (n=25) explored the effects of using intravenous ketamine to treat treatment-resistant depression (TRD) in participants over the age of 60. Depressive symptoms improved significantly, 48% of participants responded, and during the acute phase, executive function measures and the fluid cognition composite score improved (Cohen's d = 0.61).

Published
Journal
American Academy of Clinical Psychiatrists
Authors
Oughli, H. A., Gebara, M. A., Ciarleglio, A., Lavretsky, H., Brown, P. J., Flint, A. J., Farber, N. B., Karp, J. F., Mulsant, B. H., Reynolds, C. F., Roose, S. P., Yang, L., Butters, M. A., Lenze, E. J.
Open Accessindividual

Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial

In a double-blind randomised placebo-controlled trial of 29 patients with treatment-resistant depression, a single dose of ayahuasca produced rapid antidepressant effects versus placebo at days 1, 2 and 7, with effect sizes increasing from Cohen’s d = 0.84 to 1.49 and higher response rates at day 7 (64% v. 27%). This first controlled trial of a psychedelic in this population supports the safety and therapeutic potential of ayahuasca when dosed in an appropriate setting.

Published
Journal
Psychological Medicine
Authors
Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., Dos Santos, R. G., Tófoli, L. F., De Oliveira Silveira, G., Yonamine, M., Riba, J., Santos, F. R., Silva-Junior, A. A., Alchieri, J. C., Galvão-Coelho, N. L., Lobão-Soares, B., Hallak, J. E. C., Arcoverde, E., Maia-De-Oliveira, J. P., Araújo, D. B.

Quick Facts

Full Name
Clinician-Administered Dissociative States Scale
Domain
Personality / Psychological
Papers Indexed
4
Score Range
0–92
Interpretation
Lower = better
All Measures